Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6615905 | 1.00 | RAB9A (0.53) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL14919145 | 0.92 | MAPT (0.51) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL14919146 | 0.92 | MAPT (0.51) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL21410824 | 0.91 | ALDH1A1 (0.53) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL21410822 | 0.91 | ALDH1A1 (0.53) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL5276860 | 0.87 | ALDH1A1 (0.50) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL5276866 | 0.87 | ALDH1A1 (0.50) | RAB9AGAAMEN1KMT2ANPC1 | |
| SCHEMBL13555269 | 0.86 | KDM4A (0.49) | RAB9AGAAKMT2AKDM4ACPA1 | |
| SCHEMBL1333933 | 0.85 | CRHBP (0.56) | RAB9AGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1333936 | 0.85 | CRHBP (0.56) | RAB9AGAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-11905297-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3773566-A1 | OX2R COMPOUNDS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019191327-A1 | OX2R COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-0892797-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905297-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | RAB9A 1793/4885GAA 2090/4885MEN1 4617/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | RAB9A 1793/4885GAA 2090/4885MEN1 4617/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | RAB9A 1793/4885GAA 2090/4885MEN1 4617/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | RAB9A 1793/4885GAA 2090/4885MEN1 4617/4885 |
| US-20210163494-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | RAB9A 1793/4885GAA 2090/4885MEN1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.